The Effectiveness of Intensive Glycemic Control for the Prevention of Vascular Complications in Diabetes Mellitus
Tóm tắt
Obesity and type 2 diabetes mellitus have reached epidemic proportions in the US, and indeed, globally. While microvascular complications contribute to considerable morbidity, much of the excess mortality (around 70%) is due to macrovascular disease. Hyperglycemia has predictable toxic effects on multiple organs (‘glucotoxicity’) including the pancreas, where it impairs insulin secretion and insulin gene expression through mechanisms that lead to glucose densensitization and β-cell exhaustion, eventually resulting in irreversible β-cell failure. There is robust evidence to suggest that strict glycemic control reduces diabetic microvascular complications (retinopathy, nephropathy, and neuropathy) in both primary- and secondary-prevention settings. While unequivocal evidence that intensive glycemic control reduces the risk of death due to macrovascular disease is lacking, meta-analytic data and controlled clinical trial data suggest there may still be clinically significant lowering of the risk for macrovascular endpoints through strict glycemic control. Cardiovascular disease in a diabetic patient is a collusion of several factors besides hyperglycemia, such as hypertension, dyslipidemia, diffuse endothelial dysfunction, hypercoagulability, and inflammation. It is important to address lifestyle issues such as maintenance of ideal bodyweight, good dietary practice, smoking cessation, and regular exercise in the comprehensive risk management of a diabetic patient, in order to reduce the vascular complications. Large, ongoing clinical trials such as ACCORD (Action to Control Cardiovascular Risk in Diabetes) are likely to establish the potential benefits of glycemic control in preventing or postponing macrovascular complications of diabetes.
Tài liệu tham khảo
American Heart Association. Heart disease and stroke statistics: 2005 update. Dallas (TX): American Heart Association, 2005
United States Department of Health and Human Services. Centers for Disease Control and Prevention: preventing heart disease and stroke (revised July 2005) [online]. Available from URL: http://www.cdc.gov/nccdphp/publications/factsheets/Prevention/pdf/cvh/pdf [Accessed 2006 Jul 31]
Yach D, Leeder SR, Bell J, et al. Global chronic diseases [editorial]. Science 2005 Jan 21; 307(5708): 317
King H, Aubert RE, Herman WH. Global burden of diabetes, 1995–2025: prevalence, numerical estimates, and projections. Diabetes Care 1998 Sep; 21(9): 1414–31
Centers for Disease Control. National diabetes fact sheet, United States, 2005 [online]. Available from URL: http://www.cdc.gov/diabetes/pubs/pdf/ndfs_2005.pdf [Accessed 2006 Jul 31]
Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998 Jul 23; 339(4): 229–34
Kylin E. Studien über das Hypertonie-Hyperglykämie-Hyperurikämiesyndrom. Zentralblatt für Innere Medizin 1923; 44: 105–27
Reaven GM. Banting lecture 1988: role of insulin resistance in human disease. Diabetes 1988 Dec; 37(12): 1595–607
Alberti KG, Zimmet PZ. Definition, diagnosis and classification of diabetes mellitus and its complications: part 1. Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998 Jul; 15(7): 539–53
Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285: 2486–97
Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute scientific statement. Circulation 2005 Oct 25; 112(17): 2735–52
Unwin N, Shaw J, Zimmet P, et al. Impaired glucose tolerance and impaired fasting glycaemia: the current status on definition and intervention. Diabet Med 2002 Sep; 19(9): 708–23
Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: a new worldwide definition. Lancet 2005 Sep 24–30; 366(9491): 1059–62
Association AD. Standards of medical care in diabetes: 2006. Diabetes Care 2006 Jan; 29 Suppl. 1: S4–42
Sobel BE. Insulin resistance and thrombosis: a cardiologist’s view. Am J Cardiol 1999 Jul 8; 84(1A): 37J–41J
Poitout V, Robertson RP. Minireview: secondary beta-cell failure in type 2 diabetes: a convergence of glucotoxicity and lipotoxicity. Endocrinology 2002 Feb; 143(2): 339–42
Sako Y, Grill VE. Coupling of beta-cell desensitization by hyperglycemia to excessive stimulation and circulating insulin in glucose-infused rats. Diabetes 1990 Dec; 39(12): 1580–3
Leahy JL, Bumbalo LM, Chen C. Diazoxide causes recovery of beta-cell glucose responsiveness in 90% pancreatectomized diabetic rats. Diabetes 1994 Feb; 43(2): 173–9
Moran A, Zhang HJ, Olson LK, et al. Differentiation of glucose toxicity from beta cell exhaustion during the evolution of defective insulin gene expression in the pancreatic islet cell line, HIT-T15. J Clin Invest 1997 Feb 1; 99(3): 534–9
Gleason CE, Gonzalez M, Harmon JS, et al. Determinants of glucose toxicity and its reversibility in the pancreatic islet beta-cell line, HIT-T15. Am J Physiol Endocrinol Metab Nov 2000; 279(5): E997–1002
Pick A, Clark J, Kubstrup C, et al. Role of apoptosis in failure of beta-cell mass compensation for insulin resistance and beta-cell defects in the male Zucker diabetic fatty rat. Diabetes 1998 Mar; 47(3): 358–64
Donath MY, Gross DJ, Cerasi E, et al. Hyperglycemia-induced beta-cell apoptosis in pancreatic islets of Psammomys obesus during development of diabetes. Diabetes 1999 Apr; 48(4): 738–44
Bonner-Weir S, Trent DF, Honey RN, et al. Responses of neonatal rat islets to streptozotocin: limited B-cell regeneration and hyperglycemia. Diabetes 1981 Jan; 30(1): 64–9
Bonner-Weir S, Trent DF, Weir GC. Partial pancreatectomy in the rat and subsequent defect in glucose-induced insulin release. J Clin Invest 1983 Jun; 71(6): 1544–53
Leahy JL, Weir GC. Evolution of abnormal insulin secretory responses during 48-h in vivo hyperglycemia. Diabetes 1988 Feb; 37(2): 217–22
Rossetti L, Shulman GI, Zawalich W, et al. Effect of chronic hyperglycemia on in vivo insulin secretion in partially pancreatectomized rats. J Clin Invest 1987 Oct; 80(4): 1037–44
Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987 May; 79(5): 1510–5
Kosaka K, Kuzuya T, Akanuma Y, et al. Increase in insulin response after treatment of overt maturity-onset diabetes is independent of the mode of treatment. Diabetologia 1980 Jan; 18(1): 23–8
Yki-Jarvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose uptake in type I diabetes. Diabetes 1987 Aug; 36(8): 892–6
Stumvoll M, Haring H, Fritsche A. For debate: Starling’s curve of the pancreas: overuse of a concept? Horm Metab Res 2003 Jul; 35(7): 391–5
Kaiser N, Sasson S, Feener EP, et al. Differential regulation of glucose transport and transporters by glucose in vascular endothelial and smooth muscle cells. Diabetes 1993 Jan; 42(1): 80–9
Du X, Matsumura T, Edelstein D, et al. Inhibition of GAPDH activity by poly (ADP-ribose) polymerase activates three major pathways of hyperglycemic damage in endothelial cells. J Clin Invest 2003 Oct; 112(7): 1049–57
Turner RC, Holman RR. Lessons from UK Prospective Diabetes Study. Diabetes Res Clin Pract 1995 Aug; 28 Suppl.: S151–7
Most RS, Sinnock P. The epidemiology of lower extremity amputations in diabetic individuals. Diabetes Care 1983 Jan-Feb; 6(1): 87–91
Pyorala K, Laakso M, Uusitupa M. Diabetes and atherosclerosis: an epidemiologic view. Diabetes Metab Rev 1987 Apr; 3(2): 463–524
Laakso M, Lehto S. Epidemiology of risk factors for cardiovascular disease in diabetes and impaired glucose tolerance. Atherosclerosis 1998 Apr; 137 Suppl.: S65–73
Kannel WB, McGee DL. Diabetes and cardiovascular disease: the Framingham study. JAMA 1979 May 11; 241(19): 2035–8
Haffner SM, Stern MP, Hazuda HP, et al. Cardiovascular risk factors in confirmed prediabetic individuals: does the clock for coronary heart disease start ticking before the onset of clinical diabetes? JAMA 1990 Jun 6; 263(21): 2893–8
McPhillips JB, Barrett-Connor E, Wingard DL. Cardiovascular disease risk factors prior to the diagnosis of impaired glucose tolerance and non-insulin-dependent diabetes mellitus in a community of older adults. Am J Epidemiol 1990 Mar; 131(3): 443–53
Klein BE, Klein R, Lee KE. Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in beaver dam. Diabetes Care 2002 Oct; 25(10): 1790–4
Perry IJ, Wannamethee SG, Walker MK, et al. Prospective study of risk factors for development of non-insulin dependent diabetes in middle aged British men. BMJ 1995 Mar 4; 310(6979): 560–4
Hu FB, Stampfer MJ, Haffner SM, et al. Elevated risk of cardiovascular disease prior to clinical diagnosis of type 2 diabetes. Diabetes Care 2002 Jul; 25(7): 1129–34
Coutinho M, Gerstein HC, Wang Y, et al. The relationship between glucose and incident cardiovascular events: a metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999 Feb; 22(2): 233–40
Khaw KT, Wareham N, Luben R, et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). BMJ 2001 Jan 6; 322(7277): 15–8
Kuusisto J, Mykkanen L, Pyorala K, et al. NIDDM and its metabolic control predict coronary heart disease in elderly subjects. Diabetes 1994 Aug; 43(8): 960–7
UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998 Sep 12; 352(9131): 837–53
Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321(7258): 405–12
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34): UK Prospective Diabetes Study (UKPDS) Group. Lancet 1998 Sep 12; 352 (9131): 854–65
Abraira C, Colwell J, Nuttall F, et al. Cardiovascular events and correlates in the Veterans Affairs Diabetes Feasibility Trial: Veterans Affairs Cooperative Study on Glycemic Control and Complications in Type II Diabetes. Arch Intern Med 1997 Jan 27; 157(2): 181–8
Meigs JB, Singer DE, Sullivan LM, et al. Metabolic control and prevalent cardiovascular disease in non-insulin-dependent diabetes mellitus (NIDDM): the NIDDM Patient Outcome Research Team. Am J Med 1997 Jan; 102(1): 38–47
DECODE Study Group on behalf of the European Diabetes Epidemiology Group. Is the current definition for diabetes relevant to mortality risk from all causes and cardiovascular and noncardiovascular diseases? Diabetes Care 2003 Mar; 26(3): 688–96
Nakagami T. Hyperglycaemia and mortality from all causes and from cardiovascular disease in five populations of Asian origin. Diabetologia 2004 Mar; 47(3): 385–94
Selvin E, Marinopoulos S, Berkenblit G, et al. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med 2004 Sep 21; 141(6): 421–31
Effect of intensive diabetes management on macrovascular events and risk factors in the Diabetes Control and Complications Trial. Am J Cardiol 1995 May 1; 75 (14): 894–903
Effect of intensive diabetes treatment on carotid artery wall thickness in the epidemiology of diabetes interventions and complications: Epidemiology of Diabetes Interventions and Complications (EDIC) Research Group. Diabetes 1999 Feb; 48 (2): 383–90
Nathan DM, Lachin J, Cleary P, et al. Intensive diabetes therapy and carotid intima-media thickness in type 1 diabetes mellitus. N Engl J Med 2003 Jun 5; 348(23): 2294–303
Nathan DM, Cleary PA, Backlund JY, et al. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005 Dec 22; 353(25): 2643–53
The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial Research Group. N Engl J Med 1993 Sep 30; 329 (14): 977–86
Retinopathy and nephropathy in patients with type 1 diabetes four years after a trial of intensive therapy: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. N Engl J Med 2000 Feb 10; 342 (6): 381–9
Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002 May 15; 287(19): 2563–9
Reichard P, Nilsson BY, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med 1993 Jul 29; 329(5): 304–9
Tuttle KR, Bruton JL, Perusek MC, et al. Effect of strict glycemic control on renal hemodynamic response to amino acids and renal enlargement in insulin-dependent diabetes mellitus. N Engl J Med 1991 Jun 6; 324(23): 1626–32
Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995 May; 28(2): 103–17
Wang PH, Lau J, Chalmers TC. Meta-analysis of effects of intensive blood-glucose control on late complications of type I diabetes. Lancet 1993; 34: 1306–9
Bending JJ, Viberti GC, Watkins PJ, et al. Intermittent clinical proteinuria and renal function in diabetes: evolution and the effect of glycaemic control. BMJ (Clin Res Ed) 1986 Jan 11; 292(6513): 83–6
Breyer JA. Diabetic nephropathy in insulin-dependent patients. Am J Kidney Dis 1992 Dec; 20(6): 533–47
Alaveras AE, Thomas SM, Sagriotis A, et al. Promoters of progression of diabetic nephropathy: the relative roles of blood glucose and blood pressure control. Nephrol Dial Transplant 1997; 12 Suppl. 2: 71–4
Boulton AJ, Drury J, Clarke B, et al. Continuous subcutaneous insulin infusion in the management of painful diabetic neuropathy. Diabetes Care 1982 Jul–Aug; 5(4): 386–90
Amthor KF, Dahl-Jorgensen K, Berg TJ, et al. The effect of 8 years of strict glycaemic control on peripheral nerve function in IDDM patients: the Oslo Study. Diabetologia 1994 Jun; 37(6): 579–84
The effect of intensive diabetes therapy on the development and progression of neuropathy: the Diabetes Control and Complications Trial Research Group. Ann Intern Med 1995 Apr 15; 122 (8): 561–8
Azad N, Emanuele NV, Abraira C, et al. The effects of intensive glycemic control on neuropathy in the VA cooperative study on type II diabetes mellitus (VA CSDM). J Diabetes Complications 1999 Sep–Dec; 13(5–6): 307–13
Capes SE, Hunt D, Malmberg K, et al. Stress hyperglycaemia and increased risk of death after myocardial infarction in patients with and without diabetes: a systematic overview. Lancet 2000 Mar 4; 355(9206): 773–8
Malmberg K. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997 May 24; 314(7093): 1512–5
Malmberg K, Ryden L, Wedel H, et al. Intense metabolic control by means of insulin in patients with diabetes mellitus and acute myocardial infarction (DIGAMI 2): effects on mortality and morbidity. Eur Heart J 2005; 26: 650–1
Fath-Ordoubadi F, Beatt KJ. Glucose-insulin-potassium therapy for treatment of acute myocardial infarction: an overview of randomized placebo-controlled trials. Circulation 1997 Aug 19; 96(4): 1152–6
Mehta SR, Yusuf S, Diaz R, et al. Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. JAMA 2005 Jan 26; 293(4): 437–46
van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001 Nov 8; 345(19): 1359–67
Langouche L, Vanhorebeek I, Vlasselaers D, et al. Intensive insulin therapy protects the endothelium of critically ill patients. J Clin Invest 2005 Aug; 115(8): 2277–86
Langer O, Rodriguez DA, Xenakis EM, et al. Intensified versus conventional management of gestational diabetes. Am J Obstet Gynecol 1994 Apr; 170(4): 1036–46
Garner P, Okun N, Keely E, et al. A randomized controlled trial of strict glycemic control and tertiary level obstetric care versus routine obstetric care in the management of gestational diabetes: a pilot study. Am J Obstet Gynecol 1997 Jul; 177(1): 190–5
Crowther CA, Hiller JE, Moss JR, et al. Effect of treatment of gestational diabetes mellitus on pregnancy outcomes. N Engl J Med 2005 Jun 16; 352(24): 2477–86
de Veciana M, Major CA, Morgan MA, et al. Postprandial versus preprandial blood glucose monitoring in women with gestational diabetes mellitus requiring insulin therapy. N Engl J Med 1995 Nov 9; 333(19): 1237–41
Rohlfing CL, Wiedmeyer HM, Little RR, et al. Defining the relationship between plasma glucose and HbA (1c): analysis of glucose profiles and HbA (1c) in the Diabetes Control and Complications Trial. Diabetes Care 2002 Feb; 25(2): 275–8
Monnier L, Lapinski H, Colette C. Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA (1c). Diabetes Care 2003 Mar; 26(3): 881–5
Woerle HJ, Pimenta WP, Meyer C, et al. Diagnostic and therapeutic implications of relationships between fasting, 2-hour postchallenge plasma glucose and hemoglobin A1c values. Arch Intern Med 2004 Aug 9–23; 164(15): 1627–32
Gerich JE. Clinical significance, pathogenesis, and management of postprandial hyperglycemia. Arch Intern Med 2003 Jun 9; 163(11): 1306–16
Saydah SH, Loria CM, Eberhardt MS, et al. Subclinical states of glucose intolerance and risk of death in the US. Diabetes Care 2001 Mar; 24(3): 447–53
Chiasson JL, Josse RG, Gomis R, et al. Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. JAMA 2003 Jul 23; 290(4): 486–94
Hanefeld M, Cagatay M, Petrowitsch T, et al. Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients: meta-analysis of seven long-term studies. Eur Heart J 2004 Jan; 25(1): 10–6
Fonseca VA, Theuma P, Mudaliar S, et al. Diabetes treatments have differential effects on nontraditional cardiovascular risk factors. J Diabetes Complications 2006 Jan–Feb; 20(1): 14–20
Salpeter SR, Greyber E, Pasternak GA, et al. Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus: systematic review and meta-analysis. Arch Intern Med 2003 Nov 24; 163(21): 2594–602
Dormandy JA, Charbonnel B, Eckland DJ, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial. Lancet 2005 Oct 8; 366(9493): 1279–89
Schaumberg DA, Glynn RJ, Jenkins AJ, et al. Effect of intensive glycemic control on levels of markers of inflammation in type 1 diabetes mellitus in the Diabetes Control and Complications Trial. Circulation 2005 May 17; 111(19): 2446–53
Moss SE, Klein R, Klein BE, et al. The association of glycemia and cause-specific mortality in a diabetic population. Arch Intern Med 1994 Nov 14; 154(21): 2473–9
Ryan DH, Espeland MA, Foster GD, et al. Look AHEAD (Action for Health in Diabetes): design and methods for a clinical trial of weight loss for the prevention of cardiovascular disease in type 2 diabetes. Control Clin Trials 2003 Oct; 24(5): 610–28
Fradkin J. Diabetes clinical trials: what is new at NIDDK? Clin Diabetes 2004 July 1; 22(3): 109–12
Colhoun HM, Betteridge DJ, Durrington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004 Aug 21–27; 364(9435): 685–96
Prisant LM. Preventing type II diabetes mellitus. J Clin Pharmacol 2004 Apr; 44(4): 406–13
ClinicalTrials.gov. The ORIGIN trial (Outcome Reduction With Initial Glargine Intervention) [online]. Available from URL: http://www.clinicaltrials.gov/ct/show/NCT00069784 [Accessed 2006 Aug 23]
Collins R, Armitage J, Parish S, et al. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003 Jun 14; 361(9374): 2005–16
Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350: 1495–504
Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial: lipid-lowering arm (ASCOT-LLA). Diabetes Care 2005 May; 28(5): 1151–7
Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001 Sep 20; 345(12): 861–9
Dahlof B, Devereux RB, Kjeldsen SE, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar 23; 359(9311): 995–1003
Standards of medical care in diabetes. Diabetes Care 2005 Jan; 28 Suppl 1: S4-36